How it works
Masimo
rainbow SET™ technology
Philips patient monitoring with Masimo technology provides noninvasive, continuous hemoglobin monitoring you can rely on – at the point of care. Maintain consistent visibility on your patient's condition between invasive hemoglobin samples. Streamline workflows and drive down costs while providing clinically proven patient monitoring across care settings.
Standard parameters
Optional parameters
Common measurement parameters SpO2 - measure of oxygen saturation even through motion and low perfusion SpHb1 - provides continuous visibility to changes – or lack of changes – in hemoglobin levels between invasive blood samples PVi - measure of the dynamic changes in the Perfusion Index (PERF) that occur during one or more respiratory cycles
Philips IntelliVue and Masimo Horizon Trends Horizon Trends are built into many Philips IntelliVue monitors and provide graphical representation of vital sign changes to make deviations easier to notice.
Masimo rainbow SET parameters As part of the Philips / Masimo partnership, customers have access to Masimo’s noninvasive monitoring technologies in Philips IntelliVue monitors, including Masimo rainbow SET technology. The rainbow SET technology provides customers the option to purchase advance clinical measurement parameters.
Intuitive display on Masimo measurements on Philips IntelliVue monitors
Clear and intuitive screen displays combine vital signs with Masimo rainbow SET parameters – providing trend data and current data on one easy-to-read screen.
Masimo rainbow SET parameters
SPO2 noninvasive oxygen saturation SpHb noninvasive continuous hemoglobin PVi Pleth Variability index Pi PERF Perfusion index SpOC noninvasive oxygen content SpMet noninvasive methemoglobin
Horizon trends
Horizon trends clearly indicate timely changes in patient condition – to aid you to quickly identify meaningful clinical deviations and take appropriate actions.
Noninvasive rainbow SET technology
Advanced rainbow SET sensors utilize multiple wavelengths of light to measure total hemoglobin (SpHb), Pleth Variability Index (PVi), oxygen content (SpOC). carboxyhemoglobin (SpCO) and methemoglobin (SpMet) noninvasively and continuously.
Works with your IT, works for your clinical teams
Philips IntelliVue monitoring platform fits securely into your hospital’s IT environment to capture timely patient data and feed it to the EMR. Capitalize on your IT investments, support your care teams with clinically proven solutions – without the need to purchase additional equipment. With more than 1 million monitors sold since 2002, the IntelliVue family of monitoring solutions offers a proven track record for quality.
Noninvasive measurement technology – in clinical practice
Peer reviews have found that using SpHb® monitoring in conjunction with invasive blood sampling can deliver value in the ER, OR, and during transport.
In low blood loss surgical applications
Reduces unnecessary transfusions
>87% reduction in transfusion frequency (from 4.5% to 0.6%)2 >90% reduction in average units transfused (from 0.1 to 0.01 units per patient)2
In high blood loss surgical applications
Reduces unnecessary transfusions
> 73% to 32% reduction in the percentage of patients receiving 3 or more units3* > 47% reduction in average units transfused (1.9 to 1.0 per patient)3*
Initiate timely transfusions when transfusions are needed
See more about Philips and Masimo
Philips IntelliVue with rainbow SET
Versatile platform provides continuous and noninvasive patient monitoring with leading hemoglobin measurement technology.
The partnership
Philips and Masimo have teamed up to create the future of measurements and monitoring.
References
Masimo clinical claims are referenced on this web page. All studies available at www.masimo.com/evidence/featured-studies/feature/ (1) SpHb** monitoring is not intended to replace lab testing. Blood samples should be analyzed by lab instruments prior to clinical decision making. (2) (3) Awada WN et al J Clin Mon it Comput. DOI 10.1007/s10877-015-9660-4. *Study Protocol: In each group, if researchers noted SpHb trended downward below 10 g/dl, a red blood cell transfusion was started and continued until SpHb trended upward above 10 g/dl. The transfusion threshold of 10 g/dl was predetermined by the study protocol and may not be appropriate for all patients. Blood sampling was the same for the control and test group.
